Rybelsus® US approval conference call

Conference call following US approval of Rybelsus®

On 23 September 2019 at 8:00 to 8:30 AM CEST, corresponding to 2:00 to 2:30 am EST, a conference call for investors will be held.
 

To access the conference call, please call the following numbers:

Denmark:

Outside US and DK:

USA:

+45 3272 0417 (conference code 5453927#)

+44 (0) 207 192 8338 (conference code 5453927#)

+1 646 741 3167 (conference code 5453927#)


Please use the below link to access the webcast and presentation.

- Conference call link

- Conference call presentation

If you have any questions, you are welcome to contact Novo Nordisk Investor Relations: 

 

Peter Hugreffe Ankersen

 

+45 3075 9085

Valdemar Borum Svarrer

+45 3079 0301

Ann Søndermølle Rendbæk

+45 3075 2253

Kristoffer Due Berg (US)

+1 609 235 2989